Amrize Q2 revenue climbs 8.6% to $3.49B, but material weakness and a prior-period revision persist
AMRZ is trading near its 52-week low of $46.03 (0.6% above the low) on elevated volume (2.0× avg).
Summary
Amrize's Q2 2026 revenue grew 8.6% to $3.49 billion, with net income of $476 million. The filing also reveals a prior-period revision and an ongoing material weakness in internal controls.
Key Events · Earnings and Guidance · AMRZ
-
Q2 Revenue Up 8.6%
Revenue reached $3.49 billion, driven by volume growth of $200 million and contributions from acquisitions of $54 million. Net income was $476 million, up from $416 million a year ago.
-
Prior Period Revision
The company revised prior financial statements to correct an understatement of deferred revenue related to extended warranties, which was $78 million as of December 31, 2025. The correction was not material to any prior period but would be material to current results.
-
Material Weakness Unresolved
The previously disclosed material weakness in internal controls over financial reporting, related to insufficient U.S. GAAP expertise, remains unremediated. Management is continuing remediation efforts.
-
Share Buyback Active
Amrize repurchased $194 million of shares in Q2 under its $1 billion authorization, with $0.8 billion remaining. The stock closed at $53.30 on June 30, 2026, implying 15.1 million shares remaining under the program.
Analysis · AMRZ · Manufacturing
Solid Q2 results saw revenue rise 8.6% to $3.49 billion and net income reach $476 million, fueled by volume growth in Building Materials. Yet the quarter also brought a prior-period revision tied to an understatement of deferred revenue from extended warranties, and the material weakness in internal controls remains unremediated. With the stock trading near its 52-week low, the active $1 billion buyback program offers some support, but the control deficiencies and accounting corrections inject uncertainty.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRZ was trading at $46.29 on NYSE in the Manufacturing sector, with a market capitalization of approximately $25.6B. The 52-week trading range was $46.03 to $65.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.